Date of Document: February 8, 2025

CURRICULUM VITAE

Hui-Zi Chen MD, PhD

Assistant Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Health Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:

2001 - 2005 BA in Molecular and Cell Biology, Cornell University, Ithaca, NY
2005 - 2013 MD (Medical Scientist Training Program), College of Medicine and Public Health, The Ohio State University, Columbus, OH
2005 - 2011 PhD (Medical Scientist Training Program), The Ohio State University, Dept of Molecular Virology, Immunology, and Medical Genetics, Columbus, OH

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

2013 - 2015 Residency, Internal Medicine,ABIM Research Track (Physician Scientist Training Program), The Ohio State University, Columbus, OH
2015 - 2019 Fellowship, Medical Oncology, ABIM Research Track (Physician Scientist Training Program), The Ohio State University,, Columbus, OH
2016 - 2019 Post-Doctoral Fellowship, The Ohio State University Comprehensive Cancer Center, Mentor: Sameek Roychowdhury, MD, PhD, Columbus, OH
09/2019 - 01/2021 Tenure-track Assistant Professor of Internal Medicine, Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
02/2021 - Present Tenure-track Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

Board Certified	Issue Date	Expiration
Internal Medicine	2016	2026
Medical Oncology	2019	2029

AWARDS AND HONORS:

2001 - Present National Merit Achievement Scholar
2001 - 2005 Pauline & Irving Tanner Dean’s Scholar for Academic Excellence , Cornell
2003 - 2004 Summer Undergraduate Research Fellow, American Heart Association
2010 - 2011 Pelotonia Graduate Research Fellowship
2017 - 2019 Pelotonia Postdoctoral Research Fellowship
2018 ASCO Conquer Cancer Foundation Young Investigator Award
2018 Excellence in Hematology and Medical Oncology Research Award, OSU
2020 OSUCCC The James Cancer Hospital Compassionate Care Award, The James Development and Recognition Council
2020 OSUCCC Annual Scientific Meeting Invited Junior Faculty Presentation
2020 OSUCCC Annual Scientific Meeting Michael Hess Poster Award (Category: Translational Therapeutics)

2021 American Society of Clinical Investigators Young Physician Scientist Award nominee (nominated by Department Chair)

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

2011 - 2013 American Physician Scientist Association (APSA)
2013 - 2015 American College of Physicians
2015 - Present American Society of Clinical Oncology
2015 - Present American Association of Cancer Research
2021 - Present Society for Immunotherapy of Cancer
2021 - Present International Association for the Study of Lung Cancer
2022 - Present MCW Cancer Center Seminar Ambassador Group member

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	1K08 CA241309-01
Source:	NIH/NCI Mentored Clinical Scientist Research Career Development Award
Role & Effort:	PI
PI:	Chen, Hui-Zi MD
Dates:	08/01/2019 - 07/31/2024
Direct Funds:	$1,243,675 (Genomic characterization of tumor heterogeneity in recurrent small cell lung cancer through research autopsy. The overall aim of this grant is to identify mechanisms of therapeutic resistance in relapsed SCLC through an innovative approach of combining rapid research autopsy and genomics.)

Prior

Peer Review

Title:	ASCO Conquer Cancer Foundation Young Investigator Award
Source:	
Role & Effort:	PI
PI:	Chen, Hui-Zi MD
Dates:	07/01/2018 - 06/30/2019
Direct Funds:	$50,000 (Genomic characterization of tumor heterogeneity in recurrent small cell lung cancer. This independent award supported work during my post-doctoral research fellowship that generated key preliminary data utilized for the K08 grant application.)

Title:	MCWCC NGS-based Pilot Award
Source:	Transcriptomic characterization of small cell lung cancer subtypes
Role & Effort:	PI
PI:	Chen, Hui-Zi MD
Dates:	07/01/2021 - 06/30/2022
Direct Funds:	$5,000 (Intramural cancer center award for transcriptomic analyses of SCLC datasets in collaboration with GSPMC; goal of project is to identify unique gene

	networks and druggable pathways in different SCLC subtypes.)
Title:	A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280 in patients with unresectable locally advanced or metastatic cancer
Role & Effort:	Institutional PI
Title:	A Randomized, Open-label Study of HLX10 plus Chemotherapy (CarboplatinEtoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Role & Effort:	Institutional PI
Title:	An Open-Label, Randomized Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib (TAS6417) plus Pemetrexed and Cisplatin or Carboplatin, versus Pemetrexed and Cisplatin or Carboplatin, in Patients with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Role & Effort:	Institutional PI 2024
Title:	A randomized, open-label, phase 3 study of tarlatamab compared with standard of care in subjects with relapsed small cell lung cancer after platinum-based first line chemotherapy
Role & Effort:	Institutional PI
Title:	A randomized, multi-center, open-label, phase 3 study of lurbinectedin single-agent or lurbinectedin in combination with irinotecan versus investigator's choice (topotecan or irinotecan) in relapsed small cell lung cancer patients (LAGOON trial)
Role & Effort:	Institutional PI
Title:	Phase 1/2 study of VS-6766 in Combination with adagrasib in patients with KRAS G12C mutant non-small cell lung cancer
Role & Effort:	Institutional PI

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

National

"Updates in the management of SCLC", OncLive® State of the Science SummitTM on Lung Cancer, Columbus, OH, 03/2020

Regional

Precision Medicine in Design of Cancer Clinical Trials, BSGP 8800.04 Cancer Biology & Therapeutics, 03/2020

Precision Medicine, 11th Annual Advances in Hematology and Oncology Fall Symposium, Green Bay, WI, 10/2022

Precision Medicine, 2023 WAHO Annual Conference, Green Bay, WI, 09/2023

Local

Management of Hepatocellular Carcinoma, Hematology & Oncology Fellowship lecture, Milwaukee, WI, 01/2020

Communications Workgroup, MCW Cancer Center Precision Oncology Initiative, Milwaukee, WI, 2021 - Present

MCW Medical Scientist Training Program Workgroup (selected by Chair of Department of Medicine), Milwaukee, WI, 2021 - Present

Transcriptomic Analysis of Small Cell Lung Cancer, MCW Cancer Center and Genomic Sciences and Precision Medicine Center Joint Seminar, Milwaukee, WI, 04/2022

Advancing Therapies for Small Cell Lung Cancer, MCW Department of Medicine Grand Rounds, Milwaukee, WI, 04/2022

Current and Future Challenges in Treatment of Lung Cancer, MCW Department of Medicine Intern Lung Cancer Lecture, Milwaukee, WI, 05/2022

Treatment Updates for Small Cell Lung Cancer, 2022 Updates in Lung Cancer Symposium, Milwaukee, WI, 08/2022

Advancing Therapies for Small Cell Lung Cancer, MCW Cancer Center Discovery and Developmental Therapeutics Seminar, Milwaukee, WI, 09/2022

Management of Advanced Small Cell Lung Cancer, MCW Hematology & Oncology Fellowship Lecture, Milwaukee, WI, 10/2022

Introduction to Precision Medicine, MCW Department of Medicine Residents Lecture, Milwaukee, WI, 08/2023

EXTRAMURAL TEACHING:

Medical Student Education

2019 - Present The James Cancer Hospital Organ Donation Council, Physician Liaison

2020 - Present Advisory Board for Translational Oncology, Introduction to Precision Medicine

2020 - Present Department of Radiation Oncology Translational Research Seed Grants, Reviewer

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:

Clinical/Research Fellows

06/2023 UWM Fellow: Alexia Castillo, role of arginase 2 in small cell lung cancer biology, Undergraduate Research Fellowship Mentor, MCW Cancer Center & University of Wisconsin Milwaukee (UWM)

BIBLIOGRAPHY

Books, Chapters, and Reviews

1. Bonneville R, Krook MA, **Chen HZ**, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. Methods Mol Biol. 2020;2055:119-132. PMCID: PMC7010320
2. Krook M*, Paruchuri A*, Wing M*, Samorodnitsky E, Bonneville R, Reeser J, Dao T, Ernst G, Barker H, Patel A, Baker K, Wilberding M, Smith A, Zehr B, Freud A, Allenby A, **Chen HZ**, Roychowdhury S. Focused FGFR sequencing permits fusion monitoring in serial cfDNA and reveals an expanded

landscape of FGFR resistance mutations through rapid research autopsy. npj Precision Oncology, in revision.

3. Krook MA*, Bonneville R*, **Chen HZ**, Reeser JW, Wing MR, Smith AM, Dao T, Samorodnitsky E, Miya J, Yu L, Freud AG, Allenby P, Roychowdhury S. Landscape of metastatic cholangiocarcinoma through rapid research autopsy.

Abstracts

1. Rovin BH, Zhang X, **Chen HZ**, Song H, Chen X. A novel regulator of chemokine expression: linking oxidative stress to inflammation. American Society of Nephrology 37th Annual Meeting and Scientific Exposition, St. Louis, MO, 2004.
2. **Chen HZ**, Levitt P, Levy J, Xu X, Han L, Fan M, Weiss RW. Mutational analysis of the mouse Hus1 cell cycle checkpoint protein. Cornell University 20th Annual Undergraduate Research Forum, Ithaca, NY, 2005.
3. **Chen HZ**, Wang H, Wu L, de Bruin A, House M, Ng S, Johnson J, Goldenberg LE, Fang X, Fernandez SA, Stephens JA, Naidu S, Stromberg P, Rosol TJ, Shapiro CL, Leone G. Suppression of anti-tumor immunity by E2F3. Days of Molecular Medicine Conference (Human genetics, stem cells and physiology: the future of individualized medicine), Harvard Medical School, Boston, MA, 2009.
4. Speaker. Title of presentation: Mammalian Atypical E2Fs link Endocycle with Cancer. Great Lakes Mammalian Development Meeting, Toronto, Canada, 2011
5. **Chen HZ**, Krook M, Bonneville R, Kautto E, Miya J, Wing M, Reeser J, Freud A, Allenby P, Yu L, Roychowdhury S. Characterization of tumor heterogeneity through utilization of rapid research autopsy. OSUMC Annual Trainee Research Day, Columbus, OH, 2017.
6. **Chen HZ**, Krook M, Bonneville R, Kautto E, Miya J, Wing M, Reeser J, Freud A, Allenby P, Yu L, Roychowdhury S. Characterization of tumor heterogeneity through utilization of rapid research autopsy. OSUCCC Annual Scientific Meeting, Columbus, OH, 2017.
7. **Chen HZ**, Bonneville R, Samorodnitsky E, Krook MA, Miya J, Wing MR, Reeser J, Smith A, Dao T, Martin D, Guo A, Allenby P, Freud AG, Roychowdhury S. Research autopsy program for studying tumor heterogeneity and treatment resistance in advanced solid tumors. OSUCCC Annual Scientific Meeting, Columbus, OH, 2018.
8. Speaker. Title of presentation: Research Autopsy Reveals Clonal Evolution of Metastatic Small Cell Lung Cancer. Pelotonia Fellowship Symposium, Columbus, OH, 2018.
9. Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, **Chen HZ**, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich P, Hampel H. Mainstreaming germline genetic testing for patients with pancreatic cancer increases access. Familial Cancer, in press.
10. **Chen HZ**, Bonneville R, Krook M, Reeser J, Wing M, Paruchuri A, Samorodnitsky E, Miya J, Smith A, Dao T, Martin D, Yu L, Freud A, Allenby P, Carbone D, Shields P, Otterson G, Roychowdhury S. Genomic characterization of recurrent small cell lung cancer through rapid research autopsy. AACR Annual Meeting, Atlanta, GA, 2019.
11. **Chen HZ**, Bonneville R, Krook M, Reeser J, Wing M, Paruchuri A, Samorodnitsky E, Miya J, Smith A, Dao T, Martin D, Yu L, Freud A, Allenby P, Carbone D, Shields P, Otterson G, Roychowdhury S. Genomic characterization of recurrent small cell lung cancer through rapid research autopsy. OSUCCC Annual Scientific Meeting, Columbus, OH, 2019
12. Noonan AM, Lustberg MB, Schnell P, Sparreboom A, Hays J, Jin N, Abushahin L, Malalur P, Roychowdhury S, Elkhatib R, **Chen HZ**, Al Mutar S, Hu S. A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients with Metastatic Colorectal Cancer Receiving FOLOFX Chemotherapy and Bevacizumab. ASCO Annual Meeting 2020
13. Miller ED, Diaz DA, Arnett AL, Huang E, Gasior A, Malalur P, **Chen HZ**, Williams TM, Bazan JG. Identifying patterns of care for elderly patients with localized anal cancer. ASTRO 2020
14. TAK280 abstract
15. HER2 in solid tumors abstract (A. Shreenivas)

Peer Reviewed Educational Products

1. Zhang X, **Chen HZ**, Rovin BH. Unexpected sensitivity of synthetic Renilla luciferase control vectors to treatment with a cyclopentenone prostaglandin. Biotechniques. 2003 Dec;35(6):1144-6, 1148.
2. Shreenivas A, Janku F, Gouda MA, **Chen HZ**, George B, Kato S, Kurzrock R. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023 Sep 29;7(1):101. PMCID:

PMC10542332
3. Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, Cleghorn W, **Chen HZ**, Kornacker K, Liu CG, Pandit SK, Khanizadeh M, Weinstein M, Leone G, de Bruin A. Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell. 2008 Jan;14(1):62-75. PMCID: PMC2253677
4. Zhang X, Chen X, Song H, **Chen HZ**, Rovin BH. Activation of the Nrf2/antioxidant response pathway increases IL-8 expression. Eur J Immunol. 2005 Nov;35(11):3258-67.
5. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadée W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008 Aug 15;112(4):1013-21. PMCID: PMC2515137
6. **Chen HZ**, Bonneville R, Paruchuri A, Reeser JW, Wing MR, Samorodnitsky E, Krook MA, Smith AM, Dao T, Miya J, Wang W, Yu L, Freud AG, Allenby P, Cole S, Otterson G, Shields P, Carbone DP, Roychowdhury S. Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy. JTO Clin Res Rep. 2021 Apr;2(4):100164. PMCID: PMC8474405
7. Miller ED, Nalin AP, Diaz Pardo DA, Arnett AL, Huang E, Gasior AC, Malalur P, **Chen HZ**, Williams TM, Bazan JG. Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer. J Natl Compr Canc Netw. 2021 Jun 10;20(6):644-652.e2.
8. **Chen HZ**, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009 Nov;9(11):785-97. PMCID: PMC3616489
9. Martinez LA, Goluszko E, **Chen HZ**, Leone G, Post S, Lozano G, Chen Z, Chauchereau A. E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol. 2010 Jan;30(2):524-36. PMCID: PMC2798461
10. Chong JL, Wenzel PL, Sáenz-Robles MT, Nair V, Ferrey A, Hagan JP, Gomez YM, Sharma N, **Chen HZ**, Ouseph M, Wang SH, Trikha P, Culp B, Mezache L, Winton DJ, Sansom OJ, Chen D, Bremner R, Cantalupo PG, Robinson ML, Pipas JM, Leone G. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature. 2009 Dec 17;462(7275):930-4. PMCID: PMC2806193
11. Wang H, Karikomi M, Naidu S, Rajmohan R, Caserta E, **Chen HZ**, Rawahneh M, Moffitt J, Stephens JA, Fernandez SA, Weinstein M, Wang D, Sadee W, La Perle K, Stromberg P, Rosol TJ, Eng C, Ostrowski MC, Leone G. Allele-specific tumor spectrum in pten knockin mice. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5142-7. PMCID: PMC2841921
12. Wenzel PL, Chong JL, Sáenz-Robles MT, Ferrey A, Hagan JP, Gomez YM, Rajmohan R, Sharma N, **Chen HZ**, Pipas JM, Robinson ML, Leone G. Cell proliferation in the absence of E2F1-3. Dev Biol. 2011 Mar 01;351(1):35-45. PMCID: PMC3868453
13. Ouseph MM, Li J, **Chen HZ**, Pécot T, Wenzel P, Thompson JC, Comstock G, Chokshi V, Byrne M, Forde B, Chong JL, Huang K, Machiraju R, de Bruin A, Leone G. Atypical E2F repressors and activators coordinate placental development. Dev Cell. 2012 Apr 17;22(4):849-62. PMCID: PMC3483796
14. **Chen HZ**, Ouseph MM, Li J, Pécot T, Chokshi V, Kent L, Bae S, Byrne M, Duran C, Comstock G, Trikha P, Mair M, Senapati S, Martin CK, Gandhi S, Wilson N, Liu B, Huang YW, Thompson JC, Raman S, Singh S, Leone M, Machiraju R, Huang K, Mo X, Fernandez S, Kalaszczynska I, Wolgemuth DJ, Sicinski P, Huang T, Jin V, Leone G. Canonical and atypical E2Fs regulate the mammalian endocycle. Nat Cell Biol. 2012 Nov;14(11):1192-202. PMCID: PMC3616487
15. Kent LN, Rakijas JB, Pandit SK, Westendorp B, **Chen HZ**, Huntington JT, Tang X, Bae S, Srivastava A, Senapati S, Koivisto C, Martin CK, Cuitino MC, Perez M, Clouse JM, Chokshi V, Shinde N, Kladney R, Sun D, Perez-Castro A, Matondo RB, Nantasanti S, Mokry M, Huang K, Machiraju R, Fernandez S, Rosol TJ, Coppola V, Pohar KS, Pipas JM, Schmidt CR, de Bruin A, Leone G. E2f8 mediates tumor suppression in postnatal liver development. J Clin Invest. 2016 Aug 01;126(8):2955-69. PMCID: PMC4966321
16. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, **Chen HZ**, Reeser JW, Yu L, Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017. PMCID: PMC5972025
17. **Chen HZ**, Bertino EM, He K. Tumor spread through air space (STAS) is an important predictor of clinical outcome in stage IA lung adenocarcinoma. J Thorac Dis. 2017 Aug;9(8):2283-2285. PMCID: PMC5594112
18. **Chen HZ**, Bonneville R, Roychowdhury S. Implementing precision cancer medicine in the genomic era. Semin Cancer Biol. 2019 Apr;55:16-27.
19. Carr DR, Pootrakul L, **Chen HZ**, Chung CG. Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor. JAMA Dermatol. 2019 Jan 01;155(1):122-123.

20. Krook MA, **Chen HZ**, Bonneville R, Allenby P, Roychowdhury S. Rapid Research Autopsy: Piecing the Puzzle of Tumor Heterogeneity. Trends Cancer. 2019 Jan;5(1):1-5.
21. **Chen HZ**, Bonneville R, Yu L, Wing MR, Reeser JW, Krook MA, Miya J, Samorodnitsky E, Smith A, Martin D, Dao T, Guo Q, Liebner D, Freud AG, Allenby P, Roychowdhury S. Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy. Oncotarget. 2019 Jan 08;10(3):277-288. PMCID: PMC6349455
22. Krook MA, Barker H, **Chen HZ**, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):624-632. PMCID: PMC6824932
23. Krook MA, Bonneville R, **Chen HZ**, Reeser JW, Wing MR, Martin DM, Smith AM, Dao T, Samorodnitsky E, Paruchuri A, Miya J, Baker KR, Yu L, Timmers C, Dittmar K, Freud AG, Allenby P, Roychowdhury S. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug;5(4). PMCID: PMC6672025
24. Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, **Chen HZ**, Reeser JW, Wing MR, Miya J, Samorodnitsky E, Smith AM, Dao T, Martin DM, Ciombor KK, Hays J, Freud AG, Roychowdhury S. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Mol Cancer Ther. 2020 Mar;19(3):847-857. PMCID: PMC7359896
25. Paruchuri A, **Chen HZ**, Bonneville R, Reeser JW, Wing MR, Krook MA, Samorodnitsky E, Miya J, Dao T, Smith A, Freud AG, Allenby P, Roychowdhury S. Research Autopsy Demonstrates Polyclonal Acquired Resistance in a Patient With Metastatic GI Stromal Tumor. JCO Precis Oncol. 2020;4. PMCID: PMC7446505
26. Bonneville R, Paruchuri A, Wing MR, Krook MA, Reeser JW, **Chen HZ**, Dao T, Samorodnitsky E, Smith AM, Yu L, Nowacki N, Chen W, Roychowdhury S. Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing. Mol Cancer Res. 2021 Mar;19(3):465-474. PMCID: PMC7939074
27. Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, **Chen HZ**, Roychowdhury S. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021 Mar;124(5):880-892. PMCID: PMC7921129
28. Kamgar M, Maahum M, Thapa B, Szabo A, Ahmed G, Shreenivas A, Thomas J, Deepika S, Evans D, Tsai S, Christians K, Erickson B, Hall W, **Chen HZ**, Lytle N, McFall T, De Sarkar N, Patrick S, George B, Kurzrock R. ATM or CHEK2 alterations as potential biomarkers of improved outcomes with irinotecan : real-world analysis of advanced pancreatic ductal adenocarcinoma. European Journal of Cancer 2023.
29. Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, **Chen HZ**, Leone G, Hamann MT. Manzamine A mitigates androgen receptor transcription and synthesis via pertubation of E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice. Molecular Oncology 2023?
30. **Chen HZ***, Kim NH*, Nishizaki D, Nesline MK, Conroy JM, DePietro P, Pabla S, Kato S, Kurzrock R. PD-1 transcriptomic landscape across cancers : implication for immune checkpoint blockade outcome. npj Genomic Medicine, submitted.
31. Thapa B, Shreenivas A, Bylow K, **Chen HZ**, George B, Kurzrock R. Successful targeting of somatic VHL alterations with belzutifan. JCO Precision Oncology, submitted.
32. Thompson J, Griffiths C, Menon S, **Chen HZ**. Invited review. New paradigms in systemic therapies for advanced lung cancer. Neoplasia.
33. Karan D, Dubey S, Gunewardena S, Iczkowski KA, Singh M, Liu P, Poletti A, Choo YM, **Chen HZ**, Hamann MT. Manzamine A reduces androgen receptor transcription and synthesis by blocking E2F8-DNA interactions and effectively inhibits prostate tumor growth in mice. Mol Oncol. 2024 Aug;18(8):1966-1979. PMCID: PMC11306517
34. Thapa B, Shreenivas A, Bylow K, **Chen HZ**, George B, Kurzrock R. Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases. J Immunother Precis Oncol. 2024 Nov;7(4):308-313. PMCID: PMC11541926